CagriSema is Novo Nordisk’s next weight-management medicine. It puts two drugs in one weekly injection: cagrilintide, a long-acting version of the hormone amylin, and semaglutide, the GLP-1 medicine in Wegovy and Ozempic. Novo filed for FDA approval in December 2025, and a decision is expected before the end of 2026. [1] [6]
This page covers what is known as of November 21, 2026: what the drug is, what the trials found, how it compared with tirzepatide (Zepbound), and the open questions about price, coverage and access. We will update it when the FDA decides.
What is CagriSema, and how is it different from Wegovy?
Wegovy contains one active drug, semaglutide, which acts on the GLP-1 receptor. CagriSema adds a second drug, cagrilintide, which acts on amylin receptors. Amylin is a hormone the pancreas releases along with insulin after meals. Novo says the two drugs together reduce hunger and increase fullness. [4]
The version Novo submitted to the FDA is a fixed-dose combination of cagrilintide 2.4 mg and semaglutide 2.4 mg, injected under the skin once a week. If approved, Novo says it would be the first injectable treatment that combines a GLP-1 receptor agonist with an amylin analogue. [1]
Is CagriSema FDA-approved yet?
No. Here is the timeline so far:
| Date | Event |
|---|---|
| Dec 18, 2025 | Novo submits a New Drug Application to the FDA, based mainly on the REDEFINE 1 and REDEFINE 2 trials [1] |
| Feb 23, 2026 | REDEFINE 4 head-to-head results against tirzepatide: primary goal not met [4] |
| Sep 21, 2026 | REIMAGINE 5 (type 2 diabetes) and REDEFINE 9 (lower dose) topline results [5] |
| Q4 2026 | FDA decision expected, according to Novo [6] |
| Early 2027 | US launch targeted by Novo, if approved [7] |
Novo has not published an FDA target date. Until the FDA acts, CagriSema is available only to people enrolled in clinical trials.
How much weight did people lose in the CagriSema trials?
The results depend on the trial population, the dose, and how the analysis handles people who stopped treatment. The table uses the treatment-policy results from the published trials where they exist, because they count everyone who was randomized.
| Trial | Who was studied | Dose | Result |
|---|---|---|---|
| REDEFINE 1 (68 weeks) | 3,417 adults without diabetes, BMI 30 or higher, or 27 or higher with a weight-related condition | 2.4 mg/2.4 mg | −20.4% body weight vs −3.0% on placebo [2] |
| REDEFINE 2 (68 weeks) | 1,206 adults with type 2 diabetes and BMI 27 or higher | 2.4 mg/2.4 mg | −13.7% vs −3.4% on placebo [3] |
| REDEFINE 9 (68 weeks) | Adults with overweight or obesity, without diabetes | 1.0 mg/1.0 mg | −21.0% vs −2.0% on placebo, estimated as if everyone stayed on treatment [11] |
In REDEFINE 1, Novo reports an average loss of about 23% when the results are estimated as if every participant had stayed on treatment. [1] In REDEFINE 2, 73.5% of people on CagriSema reached an A1C of 6.5% or lower, versus 15.9% on placebo. [3]
The REDEFINE 1 and REDEFINE 2 results are peer-reviewed and published in the New England Journal of Medicine. REDEFINE 9 was published on November 14, 2026 in The Lancet Diabetes & Endocrinology. [2] [3] [11]
How does CagriSema compare with tirzepatide (Zepbound)?
Two trials compared CagriSema directly with tirzepatide, and they point in different directions because they tested different doses in different people.
- REDEFINE 4, obesity, full doses: 809 adults with obesity were randomized to CagriSema 2.4 mg/2.4 mg or tirzepatide 15 mg in an open-label trial. At 84 weeks, weight loss was 23.0% with CagriSema and 25.5% with tirzepatide when estimated as if everyone stayed on treatment, and 20.2% versus 23.6% when counting everyone randomized. The trial’s goal was to show CagriSema was not worse than tirzepatide, and it did not meet that goal. [4]
- REIMAGINE 5, type 2 diabetes, lower doses: CagriSema 1.0 mg/1.0 mg produced an estimated 12.4% weight loss at week 60, versus 9.1% with tirzepatide 5 mg, which Novo reports as superior. A1C fell by 1.71% and 1.67%, which met the trial’s non-inferiority goal. [5]
So at the highest doses studied in obesity, tirzepatide came out ahead. At lower doses in people with type 2 diabetes, CagriSema did better. Neither trial compared CagriSema with the highest tirzepatide dose in diabetes. For the evidence on today’s approved options, see our tirzepatide vs. semaglutide guide.
What side effects did people have on CagriSema?
The side effects were mostly the stomach effects seen with other GLP-1 medicines: nausea, vomiting, diarrhea, constipation, and abdominal pain.
- In REDEFINE 1, 79.6% of people on CagriSema reported a gastrointestinal side effect, versus 39.9% on placebo. Most were temporary and mild to moderate. [2]
- In REDEFINE 2, the figures were 72.5% versus 34.4%. [3]
- According to Novo’s filing announcement, 5.9% of people stopped CagriSema because of side effects in REDEFINE 1, versus 3.5% on placebo. In REDEFINE 2 the figures were 8.4% versus 3.0%. [8]
The final FDA label, if one is issued, will set out the official warnings and dosing schedule. Until then, the trial publications are the best source. Our GLP-1 side effects guide covers what the approved medicines in this class list today.
What is still unknown?
- Price. We found no announced US price as of November 21, 2026.
- Label and dosing. The approved doses, the dose-increase schedule and the exact indication will come from the FDA label.
- Insurance coverage. Plans decide coverage drug by drug. Many employers are already tightening GLP-1 coverage for 2027; see our guide on checking whether your employer is dropping coverage.
- Medicare. The Medicare GLP-1 Bridge currently lists Wegovy, Zepbound KwikPen and Foundayo. Whether a newly approved drug would be added has not been announced. [10]
- Longer-term data. Novo expects results from REDEFINE 11, which explores the full weight-loss potential of the 2.4 mg/2.4 mg dose, in the first half of 2027, and planned a higher-dose phase 3 trial starting in the second half of 2026. [4]
Can you get CagriSema now?
Only by taking part in a clinical trial. Trial listings are on ClinicalTrials.gov. [9]
Novo states that CagriSema is not approved in the US or the EU. [1] That means any product sold online as “CagriSema” or “cagrilintide” is not an FDA-approved medicine, whatever its label says. If you want a medicine you can get today, the approved options are covered in our GLP-1 medications guide.
The bottom line
CagriSema is the first GLP-1 and amylin combination to reach an FDA decision. The trials show large average weight loss, with stomach side effects similar to other medicines in this class. It did not beat tirzepatide at full doses in obesity. Price, coverage and the final label are still unknown, and we will update this page when the FDA decides.
This article is for education only. It is not medical advice and does not recommend any medication. Talk to your prescriber about treatment decisions.